drugset / Trial / NCT04988555
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Timeline
- Start
- 2022-02-28
- Primary completion
- 2027-06-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzomenib | Small molecule | — | Oral |
| Background | Azacitidine | Other / unclassified | — | Oral |
| Background | Cytarabine | Small molecule | — | — |
| Background | Daunorubicin | Small molecule | — | — |
| Background | Fluconazole | Small molecule | — | — |
| Background | Gilteritinib | Small molecule | — | Oral |
| Background | Posaconazole | Small molecule | — | — |
| Background | Venetoclax | Small molecule | — | Oral |
| Background | Voriconazole | Small molecule | — | — |